To evaluate how heterogeneity of the target dose and heterogeneity of intra-tumor radiosensitivity affect biologically effective dose (BED) and tumor control probability (TCP) depending on the number of fractions (Nf).The dependences of TCP and BED in the planning target volume onNfare studied using the linear-quadratic model. In the considered case, the nominal biologically effective dose(BEDnom)is fixed and the variances of the target dose (σD) and radiosensitivity (σα) are assumed to be small.By using series expansion of the survival probability of malignant cells, it is analytically shown that for smallσDandσαboth BED and TCP increase with increasingNfunder the conditionBEDnom=const.In addition, the dependences of BED and TCP onNffor different values ofσDandσαare studied by using an analytical expression for BED in the case of Gaussian distributions of both target dose and radiosensitivity.Small variations in the absorbed dose and intratumor radiosensitivity can significantly reduce BED and TCP. The decreases in these quantities can be reduced by increasing the number of fractions. The findings of this study indicate that hypofractionated regimens withNf=20and dose per fractiond≤5Gy can lead to higher BED and TCP compared to treatment regimens withNf≤5andd≥10Gy commonly used for stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1088/1361-6560/abfc8e | DOI Listing |
Phys Med Biol
November 2024
Department of Radiation Oncology, University Hospital Zurich, Rämistrasse 100, Zürich, 8091, SWITZERLAND.
Liver cancer patients may benefit from proton therapy through increase of the tumor control probability (TCP). However, proton therapy is a limited resource and may not be available for all patients. We consider combined proton-photon liver SBRT treatments (CPPT) where only some fractions are delivered with protons.
View Article and Find Full Text PDFBrain Commun
September 2024
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41121, Italy.
In preclinical studies, the anti-inflammatory drug colchicine, which has never been tested in amyotrophic lateral sclerosis, enhanced the expression of autophagy factors and inhibited accumulation of transactive response DNA-binding protein 43 kDa, a known histopathological marker of amyotrophic lateral sclerosis. This multicentre, randomized, double-blind trial enrolled patients with probable or definite amyotrophic lateral sclerosis who experienced symptom onset within the past 18 months. Patients were randomly assigned in a 1:1:1 ratio to receive colchicine at a dose of 0.
View Article and Find Full Text PDFRadiother Oncol
June 2024
Department of Radiation Oncology, Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA.
Background And Purpose: Histology was found to be an important prognostic factor for local tumor control probability (TCP) after stereotactic body radiotherapy (SBRT) of early-stage non-small-cell lung cancer (NSCLC). A histology-driven SBRT approach has not been explored in routine clinical practice and histology-dependent fractionation schemes remain unknown. Here, we analyzed pooled histologic TCP data as a function of biologically effective dose (BED) to determine histology-driven fractionation schemes for SBRT and hypofractionated radiotherapy of two predominant early-stage NSCLC histologic subtypes adenocarcinoma (ADC) and squamous cell carcinoma (SCC).
View Article and Find Full Text PDFRadiol Med
April 2024
Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS, Largo Francesco Vito 1, 00168, Rome, Italy.
Purpose: The accurate prediction of treatment response in locally advanced rectal cancer (LARC) patients undergoing MRI-guided radiotherapy (MRIgRT) is essential for optimising treatment strategies. This multi-institutional study aimed to investigate the potential of radiomics in enhancing the predictive power of a known radiobiological parameter (Early Regression Index, ERI) to evaluate treatment response in LARC patients treated with MRIgRT.
Methods: Patients from three international sites were included and divided into training and validation sets.
Radiother Oncol
May 2024
Department of Radiation Oncology, Wake Forest University School of Medicine and Atrium Health Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA.
Purpose: Stereotactic body radiation therapy (SBRT) has been emerging as an efficacious and safe treatment modality for early-stage hepatocellular carcinoma (HCC), but optimal fractionation regimens are unknown. This study aims to analyze published clinical tumor control probability (TCP) data as a function of biologically effective dose (BED) and to determine radiobiological parameters and optimal fractionation schemes for SBRT and hypofractionated radiation therapy of early-stage HCC.
Material And Methods: Clinical 1- to 5-year TCP data of 4313 patients from 41 published papers were collected for hypofractionated radiation therapy at 2.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!